Skip to main content

Table 6 Adverse events of interest (preferred terms; malignancies in ≥2 patients, serious infections in ≥2 patients, Herpes Zoster, tuberculosis and opportunistic infections)

From: Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry

 IFX (N = 890)GLM (N = 530)GLM-IV (N = 157)
N of EventsN of Patients% of PatientsRate/100 Pt-YrsN of EventsN of Patients% of PatientsRate/100 Pt-YrsN of EventsN of Patients% of PatientsRate/100 Pt-Yrs
Malignancies
 Acrochordon220.2%0.0700000000
 Basal cell carcinoma210.1%0.07220.4%0.190000
 Breast cancer550.6%0.17220.4%0.190000
 Leukemia0000320.4%0.280000
 Lung adenocarcinoma110.1%0.03220.4%0.190000
 Lymphoma220.2%0.0700000000
 Non-Hodgkin’s lymphoma220.2%0.0700000000
 Renal cell carcinoma220.2%0.0700000000
 Squamous cell carcinoma440.4%0.1400000000
 Uterine cancer220.2%0.07110.2%0.090000
Serious infections
 Arthritis bacterial430.3%0.14220.4%0.190000
 Cellulitis660.7%0.21110.2%0.090000
 Pneumonia23192.1%0.80550.9%0.46110.6%0.39
 Pyelonephritis110.1%0.03320.4%0.280000
 Sepsis330.1%0.0300000000
 Urosepsis220.2%0.07110.2%0.090000
Herpes Zoster, tuberculosis and opportunistic infections
 Herpes Zoster19192.1%0.6614132.5%1.30110.6%0.39
 Tuberculosis (disseminated)110.1%0.0300000000
 Candidiasis440.4%0.1400000000
 Histoplasmosis110.1%0.0300000000
 Onychomycosis220.2%0.0700000000